Jisandai (Bingtonsha) Medical Insurance Reimbursement Policy and Purchasing Guide

Epclusa (Epclusa) is good news for patients with chronic hepatitis C (HCV). This direct-acting antiviral drug (DAA) developed by the US company Gilead Sciences was approved by the US Food and Drug Administration (FDA) in 2016, providing a new treatment option for hepatitis C patients.

For domestic patients, Jisandai (Bingtonsha) has been officially launched and included in medical insurance, making it relatively convenient to purchase. The price is about two to three thousand yuan, but the specific costs and medical insurance reimbursement details may vary depending on the region. To ensure the accuracy of the information, it is recommended that you consult your local hospital pharmacy directly.

In addition, if patients are looking for a more affordable option, they may consider foreign generic drugs of Jisanda (Bingtonsha). The Bangladeshi and Indian versions of generic drugs have more advantages in price, usually ranging from a few hundred to more than a thousand yuan, and their drug ingredients are similar to domestic original drugs. However, when choosing this approach, be sure to ensure the reliability of the purchasing channel and consult a professional doctor for advice.

Hepatitis C, if left untreated, can cause serious liver problems, including cirrhosis and liver cancer. Although traditional interferon and ribavirin treatment options have certain efficacy, they have obvious side effects and limited efficacy.

The remarkable effect of Jisanda (Bingtonsa) is due to its unique combination of drugs: sofosbuvir and vimibuvir. Sofosbuvir can effectively inhibit HCV RNA polymerase and block virus replication; while vimibuvir can prevent HCV replication and assembly in cells, thereby reducing viral load.

Clinical studies have shown that Jisandai (Bingtonsa) can achieve durable virological cure in most patients, even those who have failed previous treatments. Its high efficiency, short cycle (usually 12 weeks) and fewer side effects make Bingtongsha the preferred drug for the treatment of hepatitis C.